Chemical: Drug
vortioxetine
PharmGKB contains no prescribing info for this . Contact us to report known genotype-based dosing guidelines, or if you are interested in developing guidelines.
Annotated Labels
- Annotation of FDA Label for vortioxetine and CYP2D6
- Annotation of EMA Label for vortioxetine and CYP2D6
- Annotation of HCSC Label for vortioxetine and CYP2D6
1. Annotation of FDA Label for vortioxetine and CYP2D6
Summary
Vortioxetine (BRINTELLIX) is indicated as a treatment for major depressive disorder. The FDA-approved drug label for vortioxetine notes that the maximum recommended dose in patients who are known CYP2D6 poor metabolizers is 10 mg/day.
There's more of this label. Read more.
2. Annotation of EMA Label for vortioxetine and CYP2D6
Summary
The EMA European Public Assessment Report (EPAR) for vortioxetine (Brintellix) contains information regarding CYP2D6 poor metabolizers, who may have higher exposure to vortioxetine when coadministered a CYP3A4 or CYP2C9 inhibitor. The EPAR recommends considering dose adjustments depending on individual patient response.
There's more of this label. Read more.
3. Annotation of HCSC Label for vortioxetine and CYP2D6
Summary
The product monograph for vortioxetine (TRINTELLIX) states that the concentration of the drug is approximately 2 times higher in CYP2D6 poor metabolizers as compared to extensive metabolizers.
There's more of this label. Read more.
PharmGKB contains no Clinical Variants that meet the highest level of criteria.
To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.
Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.
The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.
The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.
The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.
Links in the "Gene" column lead to PharmGKB Gene Pages.
List of all variant annotations for vortioxetine
| Gene ? |
Variant?
(147) |
Alternate Names ? | Chemicals ? |
Alleles
?
(+ chr strand) |
Function ? |
Amino Acid?
Translation |
|
|---|---|---|---|---|---|---|---|
CA
|
CYP2D6 | *1 | N/A | N/A | N/A | ||
|
CA
|
CYP2D6 | *4 | N/A | N/A | N/A |
Overview
- BRINTELLIX
PharmGKB Accession Id
PA166122595
Type(s):
Drug
Other Vocabularies
- RxNorm: vortioxetine (1455099)
Information pulled from DrugBank has not been reviewed by PharmGKB.
Chemical Properties
SMILES
CC1=CC(=C(C=C1)SC2=CC=CC=C2N3CCNCC3)C
Source: PubChem
InChI String
InChI=1S/C18H22N2S/c1-14-7-8-17(15(2)13-14)21-18-6-4-3-5-16(18)20-11-9-19-10-12-20/h3-8,13,19H,9-12H2,1-2H3
Source: PubChem
Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.
Curated Information ?
Curated Information ?
| Evidence | Disease |
|---|---|
| Depressive Disorder, Major |
Publications related to vortioxetine: 3
|
|
Clinical Impact of Pharmacogenetic-Guided Treatment for Patients Exhibiting Neuropsychiatric Disorders: A Randomized Controlled Trial. The primary care companion for CNS disorders. 2017. Olson Marilyn C, et al.
|
| Population pharmacokinetic meta-analysis of vortioxetine in healthy individuals. Basic & clinical pharmacology & toxicology. 2014. Areberg Johan, et al.
|
|
|
|
EMA Initiatives and Perspectives on Pharmacogenomics. British journal of clinical pharmacology. 2014. Ehmann Falk, et al.
|
LinkOuts
- PubChem Compound:
- Vortioxetine (9966051)
Clinical Trials
These are trials that mention vortioxetine and are related to either pharmacogenetics or pharmacogenomics.
NURSA Datasets
No NURSA datasets available.